Severe spontaneous vertebral fractures after denosumab discontinuation: three case reports.
Osteoporosis treatments are usually given for a limited period of time in order to balance benefits and risks. We report three cases of postmenopausal women without any previous fragility fracture who presented severe spontaneous vertebral fractures after denosumab discontinuation. We think that the occurrence of these fractures could be explained by the severe rebound effect observed after denosumab discontinuation and that a consensus regarding the end of treatment with denosumab has to be defined.
Center of Bone Diseases, Bone and Joint Department, Lausanne University Hospital, Av. Pierre-Decker 4, 1011, Lausanne, Switzerland. berengere.aubry@chuv.ch.
B
B
Aubry-Rozier
Center of Bone Diseases, Bone and Joint Department, Lausanne University Hospital, Av. Pierre-Decker 4, 1011, Lausanne, Switzerland.
E
E
Gonzalez-Rodriguez
Center of Bone Diseases, Bone and Joint Department, Lausanne University Hospital, Av. Pierre-Decker 4, 1011, Lausanne, Switzerland.
D
D
Stoll
Center of Bone Diseases, Bone and Joint Department, Lausanne University Hospital, Av. Pierre-Decker 4, 1011, Lausanne, Switzerland.
O
O
Lamy
D000368:Aged; D050071:Bone Density Conservation Agents / Q000008:administration & dosage* / Q000627:therapeutic use; D000069448:Denosumab / Q000008:administration & dosage* / Q000627:therapeutic use; D004334:Drug Administration Schedule; D005260:Female; D005598:Fractures, Spontaneous / Q000209:etiology* / Q000517:prevention & control; D006801:Humans; D008875:Middle Aged; D015663:Osteoporosis, Postmenopausal / Q000150:complications / Q000188:drug therapy; D058866:Osteoporotic Fractures / Q000209:etiology* / Q000517:prevention & control; D016103:Spinal Fractures / Q000209:etiology* / Q000517:prevention & control; D028761:Withholding Treatment
D050071:Bone Density Conservation Agents; D000069448:Denosumab
Denosumab discontinuation; Osteoporotic fracture; Osteoporotic treatment duration